GI & Endoscopy

Private equity investment in the gastroenterology space has recovered from COVID-19-related delays and is on fire to end 2020. So, what's in store for 2021?

The Removing Barriers to Colorectal Cancer Screening Act of 2020 passed the U.S. House Dec. 9 and was included in the COVID-19 relief bill the Senate cleared Dec. 21. 

COVID-19 disrupted private equity investment in the gastroenterology space but as the year comes to a close, practices are flocking to PE money establishing new platforms and growing established platforms.

Dallas-based GI Alliance expanded its Louisiana presence Dec. 17 through the acquisition of Metropolitan Gastroenterology Associates.

Dallas-based GI Alliance partnered with Gastrointestinal Associates in Jackson, Miss., expanding its presence into an eighth state, the platform announced Dec. 17.

Gastroenterologist compensation will be affected by COVID-19, ending a generally upward trend from the last several years. 

  Here are the most-read GI articles from Dec. 14-18:

The FDA accepted Takeda's new drug application for TAK-721, its eosinophilic esophagitis treatment, the company announced Dec. 15.

  Here are seven updates on GI companies and practices over the past week:

The American College of Gastroenterology released its first clinical guideline on the management of irritable bowel syndrome, published in The American Journal of Gastroenterology Dec. 14.